BACKGROUND: Extramedullary leukemia (EML) is common in pediatric acute myeloid leukemia (AML) and occurs as leukemia cells within the cerebrospinal fluid (CSF) or as a solid tumor (myeloid sarcoma-MS). The effect of MS on survival is unknown. METHODS: Patients on CCG protocols 2861, 2891, 2941, and 2961 being treated for AML with intensive-timing chemotherapy were classified for the presence of EML (CSF leukemia, CNS-MS, orbital-MS, or non-CNS MS). CSF leukemia was classified as CNS3 (>5 WBC in the CSF with blasts) and non-CSF leukemia as CNS1/2 (<5 WBC in the CSF with or without blasts). Characteristics and outcomes of these patients were compared. RESULTS: Of the 1,459 total patients, 1,206 (82%) had no EML, 154 (11%) had CSF leukemia, 19 (1%) had CNS-MS, 23 (2%) had orbital-MS, and 57 (4%) had non-CNS MS. The CR rate was significantly higher in patients with orbital-MS and CNS-MS than in those with non-MS and non-CNS MS (96% and 95% vs. 78% and 78%, P = 0.034). Patients with orbital-MS and CNS-MS had significantly higher overall survival than patients with non-CNS MS (92% and 73% vs. 38%, P < 0.001), CNS3 patients (92% and 73% vs. 51, P < 0.001), and CNS1/2 patients (92% and 73% vs. 50%, P < 0.001). Patients with orbital-MS had a significantly lower relapse rate. CONCLUSION: Patients with MS involving orbital and CNS sites had a significantly better survival than patients with non-CNS MS, with CSF leukemia, or with no EML.
BACKGROUND: Extramedullary leukemia (EML) is common in pediatric acute myeloid leukemia (AML) and occurs as leukemia cells within the cerebrospinal fluid (CSF) or as a solid tumor (myeloid sarcoma-MS). The effect of MS on survival is unknown. METHODS:Patients on CCG protocols 2861, 2891, 2941, and 2961 being treated for AML with intensive-timing chemotherapy were classified for the presence of EML (CSF leukemia, CNS-MS, orbital-MS, or non-CNS MS). CSF leukemia was classified as CNS3 (>5 WBC in the CSF with blasts) and non-CSF leukemia as CNS1/2 (<5 WBC in the CSF with or without blasts). Characteristics and outcomes of these patients were compared. RESULTS: Of the 1,459 total patients, 1,206 (82%) had no EML, 154 (11%) had CSF leukemia, 19 (1%) had CNS-MS, 23 (2%) had orbital-MS, and 57 (4%) had non-CNS MS. The CR rate was significantly higher in patients with orbital-MS and CNS-MS than in those with non-MS and non-CNS MS (96% and 95% vs. 78% and 78%, P = 0.034). Patients with orbital-MS and CNS-MS had significantly higher overall survival than patients with non-CNS MS (92% and 73% vs. 38%, P < 0.001), CNS3 patients (92% and 73% vs. 51, P < 0.001), and CNS1/2 patients (92% and 73% vs. 50%, P < 0.001). Patients with orbital-MS had a significantly lower relapse rate. CONCLUSION:Patients with MS involving orbital and CNS sites had a significantly better survival than patients with non-CNS MS, with CSF leukemia, or with no EML.
Authors: W G Woods; N Kobrinsky; J D Buckley; J W Lee; J Sanders; S Neudorf; S Gold; D R Barnard; J DeSwarte; K Dusenbery; D Kalousek; D C Arthur; B J Lange Journal: Blood Date: 1996-06-15 Impact factor: 22.113
Authors: Donna L Johnston; Todd A Alonzo; Robert B Gerbing; Beverly J Lange; William G Woods Journal: Pediatr Blood Cancer Date: 2010-09 Impact factor: 3.167
Authors: M S Felice; P A Zubizarreta; E M Alfaro; M S Gallego; A M Cygler; D A Rosso; J G Rossi; F Sackmann-Muriel Journal: Cancer Date: 2000-04-15 Impact factor: 6.860
Authors: W G Woods; N Kobrinsky; J Buckley; S Neudorf; J Sanders; L Miller; D Barnard; D Benjamin; J DeSwarte; D Kalousek Journal: J Clin Oncol Date: 1993-08 Impact factor: 44.544
Authors: Kathryn E Dusenbery; William B Howells; Diane C Arthur; Todd Alonzo; Jae Won Lee; Nathan Kobrinsky; Dorothy R Barnard; Robert J Wells; Jonathan D Buckley; Beverly J Lange; William G Woods Journal: J Pediatr Hematol Oncol Date: 2003-10 Impact factor: 1.289
Authors: Christopher Payne; William C Olivero; Bonnie Wang; Seong-Jin Moon; Arash Farahvar; Eric Chen; Huan Wang Journal: Case Rep Neurol Med Date: 2014-11-16
Authors: Allison J Kaeding; Sonali P Barwe; Anilkumar Gopalakrishnapillai; Rhonda E Ries; Todd A Alonzo; Robert B Gerbing; Colin Correnti; Michael R Loken; Lisa Eidenschink Broderson; Laura Pardo; Quy H Le; Thao Tang; Amanda R Leonti; Jenny L Smith; Cassie K Chou; Min Xu; Tim Triche; Steven M Kornblau; E Anders Kolb; Katherine Tarlock; Soheil Meshinchi Journal: Blood Adv Date: 2021-05-11